oral cyclophosphamide
Showing 1 - 25 of >10,000
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Carfilzomib, Cyclophosphamide, Dexamethasone)
Not yet recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Carfilzomib
- +2 more
- (no location specified)
Jun 8, 2023
Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)
Not yet recruiting
- Ovarian Cancer
- Pembrolizumab
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma Trial in Toulouse (Doxorubicin, Cyclophosphamide)
Recruiting
- Advanced Soft-tissue Sarcoma
- Metastatic Soft-tissue Sarcoma
-
Toulouse, FranceInstitut Claudius Reagaud-IUCT Oncopôle
Oct 6, 2022
Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer Trial in Duarte, Pasadena
Active, not recruiting
- Fallopian Tube Cancer
- +2 more
-
Duarte, California
- +1 more
Mar 17, 2022
Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor Trial in Memphis (Atezolizumab, Sorafenib, Bevacizumab)
Recruiting
- Refractory Solid Tumor
- +4 more
- Atezolizumab
- +3 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Aug 4, 2022
Thoracic Sarcomas, Thorasic Cancers, Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura Trial run by the NCI
Terminated
- Thoracic Sarcomas
- +4 more
- H1299 cell lysates
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 27, 2021
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer American Joint Committee
Recruiting
- Castration-Resistant Prostate Carcinoma
- +2 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Aug 1, 2022
Breast Cancer Trial in Chicago (Cyclophosphamide, Methotrexate, Capecitabine)
Recruiting
- Breast Cancer
- Cyclophosphamide
- +2 more
-
Chicago, IllinoisUniversity of Illinois
Oct 18, 2023
Primary Membranous Nephropathy Trial in Australia (Obinutuzumab, Oral prednisolone and cyclophosphamide)
Not yet recruiting
- Primary Membranous Nephropathy
- Obinutuzumab
- Oral prednisolone and cyclophosphamide
-
Garran, Australian Capital Territory, Australia
- +12 more
Nov 1, 2023
Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7 Trial in United States (drug, other,
Active, not recruiting
- Bilateral Breast Carcinoma
- +11 more
- Cyclophosphamide
- +4 more
-
Scottsdale, Arizona
- +11 more
Jan 12, 2023
Multiple Myeloma Trial in Pawtucket, Providence (Ixazomib, Cyclophosphamide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Ixazomib
- +2 more
-
Pawtucket, Rhode Island
- +2 more
Jul 21, 2022
AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell
Completed
- AIDS-related Diffuse Large Cell Lymphoma
- +8 more
- cyclophosphamide
- +7 more
-
Eldoret, Kenya
- +1 more
Sep 12, 2022
Multiple Myeloma Trial in Torino (velcade subcutaneous melphalan prednisone, velcade cyclophosphamide prednisone, velcade
Active, not recruiting
- Multiple Myeloma
- velcade subcutaneous melphalan prednisone
- +2 more
-
Torino, ItalyA.O.U. Città della Salute e della Scienza di Torino - SC Ematolo
Mar 24, 2022
Anemia, Sickle Cell Trial in New York (Siplizumab, Exchange Transfusion, Total Body Irradiation)
Recruiting
- Anemia, Sickle Cell
- Siplizumab
- +7 more
-
New York, New YorkColumbia University Irving Medical Center
Oct 9, 2023
DLBCL Germinal Center B-Cell Type Trial in China (Selinexor, Rituximab, Cyclophosphamide)
Recruiting
- DLBCL Germinal Center B-Cell Type
- Selinexor
- +5 more
-
Guangzhou, Guangdong, China
- +5 more
Aug 16, 2022
Neuroblastoma Trial in Houston (Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN
Active, not recruiting
- Neuroblastoma
- Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells
- Cytoxan
-
Houston, TexasTexas Children's Hospital
Mar 25, 2022
Marginal Zone Lymphoma Trial in Zhengzhou (Bortezomib, Rituximab, Epirubicin)
Recruiting
- Marginal Zone Lymphoma
- Bortezomib
- +4 more
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Aug 15, 2021
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Trial (ThisCART19A, Fludarabine Oral Tablet, Cyclophosphamide)
Not yet recruiting
- Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
- ThisCART19A
- +4 more
- (no location specified)
Oct 8, 2022
Squamous Cell Carcinoma of the Oral Cavity Trial in Worldwide (GL-0817, Hiltonol, Sargramostim)
Completed
- Squamous Cell Carcinoma of the Oral Cavity
- GL-0817
- +4 more
-
Baltimore, Maryland
- +32 more
Mar 4, 2022
Diffuse Large B Cell Lymphoma Trial in Zhengzhou (Rituximab, Lenalidomide, Cyclophosphamide)
Recruiting
- Diffuse Large B Cell Lymphoma
- Rituximab
- +6 more
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Aug 15, 2021
Metastatic Breast Cancer Trial in Beijing (Vinorelbine 40mg, Toripalimab 240mg, Bevacizumab 5 mg/kg)
Recruiting
- Metastatic Breast Cancer
- Vinorelbine 40mg
- +5 more
-
Beijing, Beijing, China
- +1 more
Feb 9, 2022
Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, radiation)
Recruiting
- Primary Myelofibrosis
- Secondary Myelofibrosis
- Allogeneic Hematopoietic Stem Cell Transplantation
- +9 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jun 21, 2022